Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus-Reference-Cited by-同舟云学术

Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

Published:2014-03-18 Issue:5 Volume:74 Page:587-610
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Keating Gillian M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-014-0199-3.pdf

Reference161 articles.

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.

2. Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opin Pharmacother. 2013;14(15):2047–58.

3. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–705.

4. European Medicines Agency. Galvus (vildagliptin): EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000771/WC500020327.pdf . Accessed 4 Nov 2013.

5. European Medicines Agency. Eucreas (vildagliptin/metformin): EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000807/WC500030594.pdf . Accessed 4 Nov 2013.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the potential of neem and tamarind gum as release retardants: Design and statistical optimisation of vildagliptin extended release matrix systems using D-optimal quadratic mixture design;International Journal of Biological Macromolecules;2024-02

2. Chiral Separation of Vildagliptin by Capillary Electrophoresis—The Study of Enantiomeric Complexation;Symmetry;2023-12-22

3. National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus;Diabetes mellitus;2023-12-06

4. Medicinal chemistry of non-peptidomimetic dipeptidyl peptidase IV (DPP IV) inhibitors for treatment of Type-2 diabetes mellitus: Insights on recent development;Journal of Molecular Structure;2023-07

5. 1,3-Dehydroadamantane and Its Derivatives: A Versatile Synthetic Platform for the Preparation of Functional Compounds with a Cage Structure. A Review;Doklady Chemistry;2023-07